Korean J Hematol 2002; 37(4):
Published online December 31, 2002
© The Korean Society of Hematology
Salvage Therapy with Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma
김도연, 임석아, 성주명, 이순남, 방수미, 이재훈, 윤성수, 김병국, 박선양, 안명주
이화여대 의과대학 내과
가천의료센터
서울대학 의과대학 내과,
한양대학 의과대학 내과
Salvage Therapy with Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Background : There are few therapeutic options for patients with multiple myeloma who relapse after autologous or allogeneic stem cell transplantation, or for patients who are refractory to conventional chemotherapy and not eligible for salvage high-dose therapy. Thalidomide, a potent antiangiogenic agent, has been suggested as an effective salvage therapy in refractory multiple myeloma. The aim of this study was to evaluate the efficacy and tolerance of thalidomide as a single agent as
multicenter trial in Korea.
Method: From February 2001 to September 2002, 28 patients from 4 institutions were included. At start of treatment, all patients had active disease and 17 (61%) had received at least one autologous transplantation.
Results: The serum or urine levels of paraprotein were reduced by at least 90 percent in two patients, at least 50 percent in three patients, and at least 25 percent in two patients; for a total response rate of 25 percent. 13 patients had stable disease and 8 patients had progressed. At least half of the patients had mild or moderate constipation and fatigue. More severe adverse effects were infrequent.
Conclusion: This study confirms that thalidomide is an effective and safe agent in patients with relapsed or refractory multiple myeloma.
Keywords Thalidomide; Multiple myeloma;
PDF
Standard view
Export citation
Share Article
Korean J Hematol 2002; 37(4): 259-264
Published online December 31, 2002
Copyright © The Korean Society of Hematology.
Salvage Therapy with Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma
김도연, 임석아, 성주명, 이순남, 방수미, 이재훈, 윤성수, 김병국, 박선양, 안명주
이화여대 의과대학 내과
가천의료센터
서울대학 의과대학 내과,
한양대학 의과대학 내과
Salvage Therapy with Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma
Do Yeun Kim, Seock Ah Im, Chu Myong Seong, Soon Nam Lee, Soo Mee Bang, Jae Hoon Lee, Sung Soo Yoon, Byoung Kook Kim, Seon Yang Park, Myung Ju Ahn
Department of Internal Medicine, Ewha Womans University College of Medicine
Gachon Medical Center
Seoul National University College of Medicine
Hanyang University College of Medicine, Seoul, Korea
Abstract
Background : There are few therapeutic options for patients with multiple myeloma who relapse after autologous or allogeneic stem cell transplantation, or for patients who are refractory to conventional chemotherapy and not eligible for salvage high-dose therapy. Thalidomide, a potent antiangiogenic agent, has been suggested as an effective salvage therapy in refractory multiple myeloma. The aim of this study was to evaluate the efficacy and tolerance of thalidomide as a single agent as
multicenter trial in Korea.
Method: From February 2001 to September 2002, 28 patients from 4 institutions were included. At start of treatment, all patients had active disease and 17 (61%) had received at least one autologous transplantation.
Results: The serum or urine levels of paraprotein were reduced by at least 90 percent in two patients, at least 50 percent in three patients, and at least 25 percent in two patients; for a total response rate of 25 percent. 13 patients had stable disease and 8 patients had progressed. At least half of the patients had mild or moderate constipation and fatigue. More severe adverse effects were infrequent.
Conclusion: This study confirms that thalidomide is an effective and safe agent in patients with relapsed or refractory multiple myeloma.
Keywords: Thalidomide, Multiple myeloma,
Previous Article
